This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Tibet Pharmaceuticals Reports Financial Results For Third Quarter Ended September 30, 2011

Tibet Pharmaceuticals, Inc. (NASDAQ: TBET), an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, today reported its financial results for the third quarter ended September 30, 2011.

Summary of Third Quarter Ended September 30, 2011 Financial Results:

  • Revenue of $8.6 million, compared to $9.0 million in Q3 2010
  • Gross profit of $2.9 million, compared to $4.7 million in Q3 2010
  • Net income of $1.6 million, compared to $3.8 million in Q3 2010
  • Fully diluted EPS of $0.11

“Tibet Pharmaceuticals and its management team faced several challenges in the third quarter, however, we remain committed to our sales initiatives and will be poised for growth as conditions improve,” said Hong Yu, CEO and Chairman of Tibet Pharmaceuticals. “Despite rising raw material costs, Tibet Pharmaceuticals maintained high revenue levels, as well as $1.6 million in net income for the third quarter of 2011. The decrease compared to the same period of 2010 was primarily due to the increasingly competitive business environment of the Chinese medicine market, especially the effects of soaring inflation which caused customers to cut back on their expenditures for health-related products and medicine. In spite of these difficulties, we remain optimistic about the long-term prospects of the Tibetan medicine sector given the continuing rise of China’s middle class, and we are taking strong measures to combat the immediate challenges we face.”

Mr. Yu continued, “For example, during the third quarter of 2011, we lowered sale prices of our products and provided promotional discounts to our customers to drive sales. We will continue to use these measures to increase sales, while simultaneously reducing our expenses in order to maximize profitability going forward.”

All of Tibet Pharmaceuticals’ current products are offered and derived from Tibetan-based traditional medicines with natural herbs and minerals found in the high-altitude, low-temperature, and pollution-free environment of Qinghai-Tibet Plateau. Tibet Pharmaceuticals currently sells 5 prescription and over-the-counter Tibetan medicine products, each of which is approved by the State Food and Drug Administration of China, also known as the SFDA.

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,894.68 -65.89 -0.39%
S&P 500 1,969.94 -8.40 -0.42%
NASDAQ 4,426.2690 -23.2950 -0.52%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs